Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form

Journal of Immunology

Volumn 175, Issue 8, 2005, Pages 5077-5086

  Mujtaba, Mustafa G ^a   Flowers, Lawrence O ^a   Patel, Chintak B ^a   Patel, Ravi A ^a   Haider, Mohammad I ^a   Johnson, Howard M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR STAT1ALPHA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR TAU; TYROSINE KINASE INHIBITOR PEPTIDE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; HUMORAL IMMUNITY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RECURRENT DISEASE; REMISSION; SPLEEN CELL; WEIGHT REDUCTION;

EID: 26844548688     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.8.5077     Document Type: Article

References (42)

1. Tsygankov, A. Y. 2003. Non-receptor tyrosine kinases. Front. Biosci. 8: S595-S635.
2. Blume-Jensen, P., and T. Hunter. 2001. Oncogenic kinase signalling. Nature 411: 355-365.
3. Laird, A. D., and J. M. Cherrington. 2003. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs 12: 51-64.
4. Capdeville, R., E. Buchdunger, J. Zimmermann, and A. Matter. 2002. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1: 493-502.
5. Kotenko, S. V., and S. Pestka. 2000. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19: 2557-2567.
6. Hanada, T., I. Kinjyo, K. Inagaki-Ohara, and A. Yoshimura. 2003. Negative regulation of cytokine signaling by CIS/SOCS family proteins and their roles in inflammatory diseases. Rev. Physiol. Biochem. Pharmacol. 149: 72-86.
7. Flowers, L. O., H. M. Johnson, M. G. Mujtaba, M. Ellis, S. Haider, and P. Subramaniam. (2004). Characterization of a peptide inhibitor of JAK2 that mimics SOCS-1 function. J. Immunol. 172: 7510-7751.
8. Larsen, L., and C. Ropke. 2002. Suppressors of cytokine signalling: SOCS. APMIS 110: 833-844.
9. Kimura, A., T. Naka, S. Nagata, I. Kawase, and T. Kishimoto. 2004. SOCS-1 suppresses TNF-α-induced apoptosis through the regulation of Jak activation. Inter. Immunol. 16: 991-999.
10. Morita, Y., T. Naka, Y. Kawazoe, M. Fujimoto, M. Narazaki, R. Nakagawa, H. Fukuyama, S. Nagata, and T. Kishimoto. 2000. Signal transducers and activators of transcription (STAT)-induce STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor α-induced cell death in fibroblast. Proc. Natl. Acad. Sci. USA 97: 5405-5410.
11. Yasukawa, H., H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, T. Imaizumi, T. Matsuda, J. N. Ihle, et al. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18: 1309-1320.
12. Flowers, L. O., P. Subramanaim, and H. Johnson. (2004). A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogens 24: 2114-2120.
13. Mujtaba, M. G., W. Streit, and H. Johnson. 1998. IFN-τ suppresses both the autoreactive humoral and cellular immune response and induces stable remission in mice with chronic experimental allergic encephalomyelitis. Cell Immunol. 186: 94-102.
14. Soos, J. M., M. G. Mujtaba, P. Subramaniam, W. Streit, and H. Johnson. 1997. Oral feeding of interferon τ can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J. Neuroimmunol. 75: 43-50.
15. Sun, D., T. Newman, V. Perry, and R. Weller. 2004. Cytokine-induced enhancement of autoimmune inflammation in the brain and spinal cord: implications for multiple sclerosis. Neuropathol. Appl. Neurobiol. 30: 374-384.
16. Glabinski, A., S. Krajewski, and J. Rafalowska. 1998. Tumor necrosis factor-α induced pathology in the rat brain: characterization of stereotaxic injection model. Folia Neuropathol. 36: 52-62.
17. Jensen, M. A., B. G. Arnason, A. Toscas, and A. Noronha. 1996. Global inhibition of IL-2 and IFN-γ secreting T cells precedes recovery from acute monophasic experimental autoimmune encephalomyelitis. J. Autoimmun. 9: 587-597.
18. Kennedy, M. K., D. S. Torrance, K. S. Picha and K. M. Mohler. 1992. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149: 2496-2505.
19. Petitto, J. M., W. J. Streit, H. Z. uang, E. Butfiloski, and J. Schiffenbauer. 2000. Interleukin-2 gene deletion produces a robust reduction in susceptibility to experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci. Lett. 285: 66-70.
20. Lutton, J. D., R. Winston, and T. C. Rodman. 2004. Multiple sclerosis: etiological mechanisms and future directions. Exp. Biol. Med. 229: 12-20.
21. Rohowsky-Kochan, C., D. Molinaro, and S. D. Cook. 2000. Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis. Mult. Scler. 6: 69-77.
22. Soos, J. M., P. Subramaniam, A. Hobeika, J. Schiffenbauer, and H. Johnson. 1995. The pregnancy recognition hormone, IFN-τ, blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J. Immunol. 155: 2747-2753.
23. Szente, B. E., I. J. Weiner, M. J. Jablonsky, N. R. Krishna, B. A. Torres, and H. M. Johnson. 1996. Structural requirements for agonist activity of a murine interferon-γ peptide. J. Interferon Cytokine Res. 16: 813.
24. Pontzer, C. H., F. Bazer, and H. Johnson. 1991. Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1. Cancer Res. 51: 5304-5307.
25. Jaskiewicz, E. 2004. Epitopes on myelin proteins recognized by autoantibodies present in multiple sclerosis patients. Postepy. Hig. Med. Dosw. 58: 472-482.
26. Wang, Z., B. He, J. Qiao, and H. Link. 1995. Suppression of experimental autoimmune myasthenia gravis and experimental allergic encephalomyelitis by oral administration of acetylcholine receptor and myelin basic protein: double tolerance. J. Neuroimmunol. 63: 79-86.
27. Zamvil, S., and L. Steinman. 1990. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8: 579-621.
28. Zamvil, S., D. Mitchell, A. Moore, K. Kitamura, L. Steinman, and J. Rothbard. 1986. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 324: 258-260.
29. Ando, D., J. Clayton, D. Kono, J. Urban, and E. Sercarz. 1989. Encephalitogenic T cells in the B10. PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell. Immunol. 124: 132-143.
30. Mujtaba, M. G., J. Soos, and H. Johnson. 1997. CD T suppressor cells mediate Interferon tau protection against experimental allergic encephalomyelitis. J. Neuroimmunol. 75: 35-42.
31. Soos, J., O. Stuve, H. M. Johnson, H. L. Weiner, and S. S. Zamvil. 2002. Oral type I IFN-τ promotes T-helper 2 bias and enhances suppression of encephalomyelitis by oral glatiramer acetate. J. Immunol. 169: 2231-2235.
32. Schmidt, S., A. Papassotiropoulos, S. Sotgiu, H. Kolsch, G. Arru, M. Fois, C. Haase, S. Schmitz, N. Konig, M. Harzheim, et al. 2003. Investigation of a genetic variation of a variable number tandem repeat polymorphism of interleukin-6 gene in patients with multiple sclerosis. J. Neurol. 250: 607-611.
33. Kumar, A., M. Commane, T. Flickinger, C. Horvath, and G. Stark. 1997. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278: 1630-1632.
34. Fotheringham, J., M. Mayne, J. Grant, and J. Geiger. 2004. Activation of adenosine receptors inhibits tumor necrosis factor-a release by decreasing TNF-α mRNA stability and p38 activity. Eur. J. Pharmacol. 497: 87-85.
35. Maier, J., C. Kincaid, A. Pagenstecher, and I. Campbell. 2002. Regulation of signal transducer and activator of transcription and suppressor of cytokine-signaling gene expression in the brain of mice with astrocyte-targeted production of interleukin-12 or experimental autoimmune encephalomyelitis. Am. J. Pathol. 160: 271-288.
36. Baetz, A., M. Frey, K. Heeg, and A. H. Dalpke. 2004. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J. Biol. Chem. 279: 54708-54715.
37. Qing, Y., A. Costa-Pereira, D. Watling, and G. R. Stark. 2005. Role of tyrosine 441 of interferon-γ receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation. J. Biol. Chem. 280: 1849-1853.
38. Sasaki, A., H. Yaukawa, A. Suzuki, S. Kaminzono, T. Syoda, I. Kinjyo, M. Sasaki, J. Johnston, and A. Yoshimura. 1999. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4: 339-351.
39. Kubo, M., T. Hanada, and A. Yoshimura. 2003. Suppressors of cytokine signaling and immunity. Nat. Immunol. 4: 1169-1176.
40. Starr, R., D. Metcalf, A. G. Elefanty, M. Brysha, T. A. Willson, N. A. Nicola, D. J. Hilton, and W. S. Alexander. 1998. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. USA 95: 14395-14399.
41. Metcalf, D., W. S. Alexander, A. G. Elefanty, N. A. Nicola, D. J. Hilton, R. Starr, S. Mifsud, and L. Di Rago. 1998. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia 13: 926-934.
42. Iwamoto, T., T. Senga, Y. Naito, S. Matsuda, Y. Miyake, A. Yoshimura, and M. Hamaguchi. 2000. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation. Oncogene 19: 4795-4801.